TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of the Echo test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant Murley Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 25(OH)D measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Onset of Hepatic Encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of orality disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the insulin concentration curve (AUCins) 0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the glucose infusion rate curve (AUCGIR) 0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed insulin concentration (Cins.max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Victorian Institute of Sport Assessment-patellar Tendon (VISA-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate Ratio of the Percent of Patients Indicated for Statin With Guideline-appropriate Prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate Ratio of the Percent of Patients Indicated for ACE/ARB With Guideline-appropriate Prescription
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to caecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: SELENA-SLEDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic risk factors of TAO predisposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event rate of biopsy-proven acute rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response Rate for Participants Who Achieve a CR or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to characterize the disease course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genomic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of complete abortions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU 28-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: risk of fetal or neonatal loss
Endpoint domain: Mortality/survival
Primary endpoint: intrauterine fetal death
Endpoint domain: Mortality/survival
Primary endpoint: birth prior to 34 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Tirzepatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic quality of tympanic membrane images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease in IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in size of micro- or macroadenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in technical skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influence on ability to learn didactic information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Influence on decision-making ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SSTI Recurrence Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Direct cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency and duration of institutional care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: T. Pallidum-specific antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to TCA plasma concentration in the therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from dosing to the maximum concentration (tmax) of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episode of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clear stent capture rate (CSCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Post-baseline Tolerability Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Accuracy on Cognitive Training Quizzes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximal Mucositis grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline liver steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline steatohepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from 0-24hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized growth hormone secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: intra-and inter-individual variance in pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Resolution of Primary Injected Wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in aGVHD organ stages and overall clinical grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recurrence without metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline in PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Moderate-Severe Shigellosis Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete Response (CR) at End of Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude and character of the adaptive immune response to flu vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effects of chronic immunosuppressive therapies on innate immunity during response to flu vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transcriptional and protein signatures of the response to flu vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinically Significant Rebleeding Within 72 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients completing at least 3 doses of drug therapy without dose limiting toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events graded according to CTCAE version 4 or the Clavien-Dindo classification
Endpoint domain: Adverse events/effects
Primary endpoint: Bioavailability of solid formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voriconazole trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Haplo-derived Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of aviremic patients with detectable viral loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Types and Levels of Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between ACT point-of-care test and Anti-Xa-activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation between APTT point-of-care test and coagulation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With a Laboratory Abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With HBV DNA <Lower Limit of Quantification (LLOQ) at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of malondialdehyde (μmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline probing depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline bleeding score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: acute complications after lumpectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient decisions and perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in post-void residual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Functional Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Microparticle elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stuttering Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in microvascular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: [11C]diprenorphine binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD response to fMRI tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from device and procedure related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from target limb amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: accessing care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in clinical laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous adverse event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HDL Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in LDL Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in PSPRS measures of progressive supranuclear palsy (PSP) severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in UMSARS measures of multiple system atrophy (MSA) severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Hoehn and Yahr (H&Y) and modified H&Y Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in HbA1c from baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Athlete's opinion/experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Stomatitis
Endpoint domain: Adverse events/effects
Primary endpoint: O-desmethyltramadol to tramadol blood concentration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogic pain scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: amount of intra-operative hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: % of Participants Free of Disease Progression at 4mos
Endpoint domain: Mortality/survival
Primary endpoint: Copeptin concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of Arm Shoulder and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence and severity of Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to Cardioprotective Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nicotine tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of clinical implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increased functional behavior assessment procedural fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leptomeningeal disease-related neurological progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Displacement of fracture, measured by radial height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Displacement of fracture, measured by volar tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Displacement of fracture, measured by radial inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand (DASH) outcome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wong-Baker FACES Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of urine collection technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: esophageal detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: esophageal grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance Vision measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defocus curve measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accommodation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of focus measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving indulgence frequency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease recurrence and progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to BCG treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores at motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants admitted to Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline on the total severity of the CAPS-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomously defined clinical responder status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinical Laboratory Toxicities Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Vital Sign Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health behavior adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to start antipsychotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity One Week After Lens Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity at Time of Initial Fit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of FCT assessed by OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaque burden by IVUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fine Facial Line Evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective lung volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in health status scores from self-administered questionnaires on COPD-related disease from Weeks 0 to 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in maximal insulin secretory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SARS-CoV-2 glycoprotein-specific antibodies titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Virus-neutralizing antibodies titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of triapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability to Remain on Initial Injectable Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Doses of the sedative agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Fat Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients treated with surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of patients treated with conservative treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Measure of cardiac activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Estimate of the hormonal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean number of COSs per patient randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Patients With a 10mmHg or Greater Reduction in Office Cuff Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Group A (Rheos® Device On) Patients Who Maintain a 10 mm Hg Drop in Systolic Blood Pressure at 12 Months Post-activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serious Procedure- or System-related Adverse Event-free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from clinically-driven TLR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of TLR/TVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of ketofol in sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repeat pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Exhaled NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in healthiness of household food supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in social isolation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in social anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in shame-proneness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in social anxiety disorder clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasopressor dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time on vasopressor support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma citrulline concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of citrulline appearance (Rapp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant of citrulline removal (krem)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment time until failure
Endpoint domain: Mortality/survival
Primary endpoint: Treatment emergent adverse events (TEAEs) by severity
Endpoint domain: Adverse events/effects